Application Note: WB: 1-3μg/ml. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
Calculated MW: 23
Positive Control: The peptide used to generate this antibody is available for purchase (GTX89978-PEP).
Specificity/Sensitivity: This antibody is expected to recognize both reported isoforms (NP_066273.1; NP_001019979.1).
Form: Liquid
Buffer (with preservative): TBS, 0.5% BSA, 0.02% Sodium azide.
Concentration: 0.50 mg/ml (Please refer to the vial label for the specific concentration.)
Background: This gene is directly involved, with Myc and IgH, in a three-way gene translocation in a Burkitt lymphoma cell line. As a result of the gene translocation, the N-terminal region of the gene product is disrupted, which is thought to be related to the pathogenesis of a subset of high-grade B cell non-Hodgkin lymphoma. The N-terminal segment involved in the translocation includes the region that shares a strong sequence similarity with those of BCL7B and BCL7C. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Uniprot ID: Q4VC05
Antigen Species: Human
Immunogen: Peptide with sequence C-MKLEASQQNSEEM, from the C Terminus of the protein sequence according to NP_066273.1; NP_001019979.1.
Purification: Purified by ammonium sulphate precipitation followed by antigen affinity chromatography
Conjugation: Unconjugated
Full Name: BAF chromatin remodeling complex subunit BCL7A
English
Deutsch
